In patients with moderate peripheral artery disease, use of GLP-1 RAs increases the likelihood of more favorable cardiovascular and major limb outcomes.

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...

Semaglutide use may be increasing worldwide rates of ischemic optic neuropathy and retinal adverse events, a study suggests.

Canada: A recent observational cohort study from Canada revealed that older diabetic patients taking GLP-1 receptor ...

New guidelines from the Society for Perioperative Assessment and Quality Improvement advise patients using GLP-1 medications for weight loss to fast for a longer period of time preoperatively, ...

Navitus, the nation’s first transparent, pass-through pharmacy benefit manager (PBM), released its ninth annual Drug Trend ...

HealthDay News — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular ...

GLP-1 RAs may significantly increase the risk of neovascular age-related macular degeneration in older adults with diabetes.